CASE PRESENTATIONS {#s1}
==================

Patient MR94 II-1 was a 7-yr-old boy born to nonconsanguineous Japanese parents. He was born through normal delivery without asphyxia at 38 wk of gestation. His weight and head circumferences were 2720 g (−0.7 SD) and 31.5 cm (−1.3 SD), respectively. He acquired head control after age 3 yr, sat independently after age 6, but could not form words. He had a febrile convulsion at the age of 2 yr. When he was 5 yr old, his developmental quotient (DQ) was 12. When he was 6 yr 3 mo old, he suffered spastic quadriplegia and horizontal nystagmus. He showed no aggressive, hyperactive, or self-harming behavior but did show autistic stereotype movement. Hypotonia in his trunk, extremities, and facial muscles was noted. His height, weight, and head circumference were 100 cm (−3.0 SD), 14.6 kg (−1.8 SD), and 47 cm (−2.6 SD), respectively. Brain magnetic resonance imaging (MRI) showed cerebral white matter and midbrain atrophy, and a thin corpus callosum ([Fig. 1](#MCS003988IIDF1){ref-type="fig"}AB; [Table 1](#MCS003988IIDTB1){ref-type="table"}). His younger brother (MR94 II-2) also had X-linked intellectual disability (XLID). He was delivered by Caesarean section because of the breech presentation without asphyxia at 38 wk of gestation. His weight and head circumferences were 2878 g (−0.3 SD) and 30.5 cm (−2.0 SD), respectively. He rolled over after he was 1 yr old, but at the age of 1 yr and 2 mo, he had no head control, could not form words, and had a DQ \< 10. He also showed spastic quadriplegia. His height, weight, and head circumference were 70 cm (−2.7 SD), 6.8 kg (−3.1SD), and 43 cm (−2.3 SD), respectively. No behavioral problems were noted, but autistic features were observed. Hypotonia in his trunk, extremities, and facial muscles was also noted. A brain MRI showed cerebral atrophy, myelination delay, and a thin corpus callosum ([Fig. 1](#MCS003988IIDF1){ref-type="fig"}C).

![A *PAK3* pathogenic variant in a Japanese family with X-linked intellectual disability (XLID). (*A*,*B*) Coronal and sagittal sections of T1-weighted magnetic resonance images of patient MR94 II-1. (*C*) A coronal section of T1-weighted magnetic resonance images of patient MR94 II-2. Reduced volume of the white matter and midbrain, as well as a thin corpus callosum, were noted. (*D*) Pedigree of family MR94. (*E*) Electrochromatogram of the *PAK3* pathogenic variant, c.1282T\>A, identified in two patients in family MR94.](MCS003988Iid_F1){#MCS003988IIDF1}

###### 

Clinical features of patients with c.1282A\>T (p.W428R) and reported patients with pathogenic variants in *PAK3*

  Phenotypic features                      Patient 1              Patient 2     Sample number   Positive rate (%)
  ---------------------------------------- ---------------------- ------------- --------------- -------------------
  Variant                                  c.1282A\>T (p.W428R)                                 
  Intellectual disability                  Yes, severe            Yes, severe   34/38           89.5
  Epileptic seizures                       Yes                    No            9/39            23.1
  Autistic features                        Yes                    Yes           6/38            15.8
  Aggressive behavior/self-injury          No                     No            10/38           26.3
  Global developmental delay               Yes                    Yes           32/41           78.0
  Language impairment                      Yes                    Yes           36/37           97.3
  Spastic quadriplegia                     Yes                    Yes           4/40^a^         10.0
  Nystagmus                                Yes                    Yes           4/40^b^         10.0
  Hypotonia in the trunk and extremities   Yes                    Yes           12/35           34.3
  Hypotonia in the face                    Yes                    Yes           12/39           30.8
  Microcephaly                             Yes                    Yes           14/40           35.0
  Short stature                            Yes                    Yes           6/38            15.8
  Low set ear                              Yes                    Yes           6/38            15.8
  Long face                                Yes                    No            10/40^c^        25.0
  White matter atrophy                     Yes                    Yes           2/8             25.0
  Midbrain atrophy                         Yes                    Yes           3/10            30.0
  Hypoplasia of the corpus callosum        Yes                    Yes           6/9^d^          66.7

^a^Including hemiplegia and lower limb spasticity.

^b^Including abnormality of eye movement.

^c^Including abnormal face shape.

^d^Including dysplastic corpus callosum and agenesis of corpus callosum.

VARIANT INTERPRETATION {#s2}
======================

We identified a hemizygous missense variant, c.1282T\>A (p.W428R; GRch37. Chr X. 110439743), in the p21-activated serine/threonine kinase 3 gene (*PAK3:* NM_002578.3; OMIM300142) in MR94 II-1 and MR94 II-2 ([Fig. 1](#MCS003988IIDF1){ref-type="fig"}D,E; [Table 2](#MCS003988IIDTB2){ref-type="table"}). The variant was inherited from their mother, who is asymptomatic. The altered amino acid residue (p.W428) is located within the highly conserved kinase domain. The tryptophan residue is conserved from human to zebrafish ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003988/-/DC1)). Hence, we expected that the variant would abolish the kinase activity of *PAK3*. A c.1282T\>A variant in PAK3 has not been deposited in any database, including dbSNP build 151, ESP6500, 1000 Genomes, the Exome Aggregation Consortium, the Human Genetic Variation Database, the Genome Aggregation Database (gnomAD), ClinVar, or the Medical Genomics Japan Variant Database (as of the middle of December, 2018). We also searched the data from 3275 members of the Japanese general population acquired using high-depth whole-genome sequencing ([@MCS003988IIDC7]). However, not even a heterozygous carrier was found. Hence, the *PAK3* variant identified in this study is considered to be "an extremely rare variant." In addition, three mutation prediction tools, SIFT, PolyPhen-2, and MutationTaster, predicted the mutation to be "Damaging," with a score of 0, "Probably damaging," with a score 1, and "Disease causing," with a score of 0.99, respectively. Finally, we classified and evaluated this variant using the guidelines for the classification of sequence variants from the American College of Medical Genetics and Genomics ([@MCS003988IIDC8]). We concluded that the variant identified in this family is "Class 4 (likely pathogenic)" ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003988/-/DC1)). No pathogenic variants in other genes are identified. Array comparative genomic hybridization (aCGH) analyses in both parents and patients also identified no pathogenic copy number variants ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003988/-/DC1)).

###### 

Genomic findings and variant interpretation

  Gene     Chromosome   HGVS DNA reference         HGVS protein reference   Variant type   Predicted effect (substitution, deletion, etc.)   dbSNP/dbVar ID   Genotype (heterozygous/homozygous)   ClinVar ID (optional)  Parent of origin (optional)    Observed effect (if shown to be different from the predicted effect) (optional)  Comments (optional)
  -------- ------------ ------------------------- ------------------------ -------------- ------------------------------------------------- ---------------- ------------------------------------ ----------------------- ----------------------------- --------------------------------------------------------------------------------- ----------------------------
  *PAK3*   X            NM_002578.3: c.1282T\>A           p.W428R             Missense                      Substitution                          None                    Hemizygous                   SCV000914231       X-linked recessive                                                  None                                        Class 4, likely pathogenic

SUMMARY {#s3}
=======

Families with a Chromosome X--linked inheritance pattern ID account for 5%--10% of all ID cases, suggesting an important role of the genes mutated on the X chromosome in males ([@MCS003988IIDC4]). X-linked intellectual disability is divided into syndromic XLID (S-XLID) and nonsyndromic XLID (NS-XLID), the latter lacking dysmorphic features or other distinguishing symptoms ([@MCS003988IIDC9]). To date, at least 141 genes responsible for S-XLID and NS-XLID have been reported ([@MCS003988IIDC6]). Among them, *PAK3* was identified as the causative gene in patients with NS-XLID (OMIM300558; MRX30) ([@MCS003988IIDC1]). Currently, 10 types of point mutations, one splicing mutation, one small deletion, and a 90-kb deletion containing exons 6--18 are described in the Human Gene Mutation Database, Professional (Version: 2018.3) as of the middle of December, 2018. These are all found in non-Japanese individuals.

The clinical phenotypes of the patients with *PAK3* mutations are variable, as summarized ([Table 1](#MCS003988IIDTB1){ref-type="table"}; [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003988/-/DC1)). We noted several common features, including mild to severe ID (89.5%), language impairment (97.3%), and global developmental delay (78%), as also reported previously ([@MCS003988IIDC2]; [@MCS003988IIDC3]). Microcephaly (35.0%) and hypotonia (trunk and extremities, 34.3%; face, 30.8%) may represent characteristic features of the patients with *PAK3* mutations. Spastic paraplegia/hemiplegia (10%) and nystagmus (10%) were also found in multiple cases. Less frequent and nonspecific features include epileptic seizures (23.1%), autistic features (15.8%), aggressive behavior/self-injury (26.3%), and short stature (15.8%). Imaging findings were available only in a small number of patients, but hypoplasia of corpus callosum (66.7%), atrophy of midbrain (30.0%), and white matter (25%) were reported.

Our cases showed all features in [Table 1](#MCS003988IIDTB1){ref-type="table"} except for aggressive behavior. They also showed more severe ID compared with previously reported patients, suggesting that they had the most severe form of the disease caused by *PAK3* mutations. Spastic quadriplegia and nystagmus appear to be rare phenotypes, but similar manifestations (i.e., lower limb spasticity and hemiplegia and oculomotor abnormalities) were also reported in other patients, suggesting that these features are possibly associated with *PAK3* mutations. [@MCS003988IIDC2] reported a monozygotic twin who presented with ID, behavioral problems, and unique macrocephaly caused by a p.Y427H mutation in PAK3, which is located one amino acid prior to the residue mutated in the present patients, who had acquired microcephaly, as seen in other patients. Reason for this opposite phenotypic expression remains unknown.

In conclusion, we report the first Japanese XLID family with a novel hemizygous *PAK3* mutation. The literature review illustrated the phenotypic spectrum of PAK3-associated XLID and suggested that our cases represent a severe form of the disease.

METHODS {#s4}
=======

The biobank at the National Center of Neurology and Psychiatry is part of the National BioBank Network in Japan, which is a unique biorepository exclusively dedicated to collecting samples from patients with neuropsychiatric, muscular, and developmental diseases. The biobank contains DNA samples and clinical information from 583 families with neurodevelopmental diseases that were preserved and diagnosed from 2004 to 2016.

We performed exome sequencing to identify the causative gene in the family. Genomic DNAs were extracted from the patients and the parent\'s bloods by standard protocol. DNAs were processed by SureSelect XT Human All Exon V6 (Agilent Technologies) and BGISEQ DNA library preparation kit (BGI). Captured DNAs were sequenced using MGISEQ2000 (BGI) with 100-bp pair-end reads. Reads were mapped to the human genome reference (GRCh37/hg19) by BWA 0.7.5a-r405. Duplicated reads were removed by Picard 1.99. Variants were identified by Genome Analysis Toolkit v3.5 based on GATK Best Practice Workflow and annotated by ANNOVAR (2018 April 16). In all subjects, at least 98.1% of all coding regions were covered in 10 reads depth ([Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003988/-/DC1)). The variant in *PAK3* was confirmed by Sanger sequencing.

For the aCGH analysis, we utilized SurePrint G3 Human CGH microarray 8 × 60K (Agilent). The experimental procedures were performed according to the manufacturer\'s protocol (Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis, Version 7.2, Agilent Technologies).

The following Web resources were used: dbSNP build 151: <https://www.ncbi.nlm.nih.gov/projects/SNP/>ESP6500: <http://evs.gs.washington.edu/EVS/>1000 Genomes: <http://grch37.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG00000077264;r=X:110187513-110470589>Exome Aggregation Consortium: <http://exac.broadinstitute.org>Human Genetic Variation Database: <http://www.hgvd.genome.med.kyoto-u.ac.jp>gnomAD: <http://gnomad.broadinstitute.org>ClinVar: <https://www.ncbi.nlm.nih.gov/clinvar/>Medical Genomics Japan Variant Database: <https://mgend.med.kyoto-u.ac.jp>OMIM (MRX30): <https://www.omim.org/entry/300558?search=x-linked%20intellectual%20disability%20and%20pak3&highlight=disability%20intellectual%20xlinked%20x%20linked%20pak3>

ADDITIONAL INFORMATION {#s5}
======================
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*PAK3* variant data was submitted to the ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>) and are available under accession number SCV000914231.
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